Biotech · Public company · San Diego, CA, US
Acadia Pharmaceuticals Inc
Ticker ACAD · SEC CIK 0001070494
Track this companyFree. Adds Acadia Pharmaceuticals Inc to your Dealase workspace and tells you when its record changes.
Clinical trials258 recruiting or active
Pipeline programs14From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline14
- ACP-204Phase 3 · Lewy Body Dementia PsychosisClinicalTrials.gov · fetched Nov 12, 2026
- ACP-204Phase 3 · Alzheimer's Disease PsychosisClinicalTrials.gov · fetched Nov 12, 2026
- CarbetocinPhase 3 · Hyperphagia in Prader-Willi SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- PimavanserinPhase 3 · SchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
- PimavanserinPhase 3 · Irritability Associated With Autism Spectrum DisorderClinicalTrials.gov · fetched Nov 12, 2026
- PimavanserinPhase 3 · Neuropsychiatric Symptoms Related to Neurodegenerative DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- trofinetidePhase 3 · Rett SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- ACP-044 Dose APhase 2 · Acute Postoperative PainClinicalTrials.gov · fetched Nov 12, 2026
- ACP-044 Dose APhase 2 · Osteoarthritis PainClinicalTrials.gov · fetched Nov 12, 2026
- ACP-044 Dose BPhase 2 · Osteoarthritis PainClinicalTrials.gov · fetched Nov 12, 2026
- ACP-044 Dose BPhase 2 · Acute Postoperative PainClinicalTrials.gov · fetched Nov 12, 2026
- ACP-104Phase 2 · SchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
- ACP-211Phase 2 · Major Depressive Disorder (MDD)ClinicalTrials.gov · fetched Nov 12, 2026
- PimavanserinParkinson Disease PsychosisClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant ResponsePHASE2 · RECRUITING · started Nov 14, 2025ClinicalTrials.gov NCT07284667 · fetched Nov 12, 2026
- Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia PsychosisPHASE3 · RECRUITING · started Nov 14, 2025ClinicalTrials.gov NCT07095465 · fetched Nov 12, 2026
- Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum DisorderPHASE2 · RECRUITING · started Oct 1, 2025ClinicalTrials.gov NCT05999240 · fetched Nov 12, 2026
- Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia PsychosisPHASE2 · RECRUITING · started Aug 6, 2025ClinicalTrials.gov NCT07029581 · fetched Nov 12, 2026
- Pimavanserin and Aggression and Social Cognition.PHASE2 · RECRUITING · started Aug 1, 2024ClinicalTrials.gov NCT05895513 · fetched Nov 12, 2026
- ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension StudyPHASE3 · ENROLLING_BY_INVITATION · started Apr 23, 2024ClinicalTrials.gov NCT06194799 · fetched Nov 12, 2026
- OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi SyndromePHASE3 · TERMINATED · started Mar 11, 2024ClinicalTrials.gov NCT06420297 · fetched Nov 12, 2026
- Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi SyndromePHASE3 · COMPLETED · started Nov 27, 2023ClinicalTrials.gov NCT06173531 · fetched Nov 12, 2026
- ACP-204 in Adults With Alzheimer's Disease PsychosisPHASE2_PHASE3 · RECRUITING · started Nov 14, 2023ClinicalTrials.gov NCT06159673 · fetched Nov 12, 2026
- Pimavanserin for Sleep in Parkinson DiseaseEARLY_PHASE1 · WITHDRAWN · started Jan 27, 2023ClinicalTrials.gov NCT05796167 · fetched Nov 12, 2026
- Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative DiseasesPHASE4 · RECRUITING · started Jan 23, 2023ClinicalTrials.gov NCT05357612 · fetched Nov 12, 2026
- Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum DisorderPHASE2_PHASE3 · TERMINATED · started Nov 2, 2022ClinicalTrials.gov NCT05555615 · fetched Nov 12, 2026
- Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum DisorderPHASE2_PHASE3 · COMPLETED · started Aug 9, 2022ClinicalTrials.gov NCT05523895 · fetched Nov 12, 2026
- An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett SyndromePHASE2_PHASE3 · TERMINATED · started Sep 22, 2021ClinicalTrials.gov NCT04988867 · fetched Nov 12, 2026
- Evaluate the Efficacy and Safety of ACP-044 in Subjects With Pain Associated With Osteoarthritis of the KneePHASE2 · TERMINATED · started Jul 20, 2021ClinicalTrials.gov NCT05008835 · fetched Nov 12, 2026
- Evaluate the Efficacy and Safety of ACP-044 for the Treatment of Acute Postoperative Pain Following BunionectomyPHASE2 · COMPLETED · started Mar 29, 2021ClinicalTrials.gov NCT04855240 · fetched Nov 12, 2026
- Open-Label Extension Study of Trofinetide for Rett SyndromePHASE3 · TERMINATED · started Nov 8, 2020ClinicalTrials.gov NCT04776746 · fetched Nov 12, 2026
- Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease PsychosisPHASE4 · COMPLETED · started Feb 10, 2020ClinicalTrials.gov NCT04292223 · fetched Nov 12, 2026
- Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett SyndromePHASE3 · COMPLETED · started Jan 29, 2020ClinicalTrials.gov NCT04279314 · fetched Nov 12, 2026
- Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)PHASE3 · COMPLETED · started Nov 6, 2019ClinicalTrials.gov NCT04181723 · fetched Nov 12, 2026
- Characterization and Progression of Minor Phenomena in Parkinson's Disease (PD)COMPLETED · started Apr 25, 2019ClinicalTrials.gov NCT05240339 · fetched Nov 12, 2026
- Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative DiseasePHASE3 · COMPLETED · started Jul 17, 2018ClinicalTrials.gov NCT03623321 · fetched Nov 12, 2026
- A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative DiseasePHASE3 · COMPLETED · started May 21, 2018ClinicalTrials.gov NCT03575052 · fetched Nov 12, 2026
- Extension Study of Pimavanserin for the Adjunctive Treatment of SchizophreniaPHASE3 · TERMINATED · started Jan 1, 2017ClinicalTrials.gov NCT03121586 · fetched Nov 12, 2026
- ACP-104 in Acutely Psychotic Subjects With SchizophreniaPHASE2 · COMPLETED · started Jun 1, 2007ClinicalTrials.gov NCT00490516 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 23, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 24, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 11, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 29, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 7, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 1, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 5, 2026 · fetched Nov 12, 2026